BCRX

Business Context and Reporting Period

Company: BioCryst Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2008
Business Overview: BioCryst is a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule drugs. Key programs include peramivir (influenza), forodesine HCl (T-cell lymphoma/leukemia), and BCX-4208 (psoriasis/autoimmune). The company has not yet commercialized any products and relies on collaborative agreements and government contracts for revenue.

Key Financial Metrics

Note: Total Cash, Equivalents & Marketable Securities calculated as Cash ($27,875) + Current Marketable Securities ($17,674) + Non-Current Marketable Securities ($35,617).

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 17.6% to $10.8 million, driven primarily by reimbursements from the U.S. Department of Health and Human Services (HHS) for the peramivir program and amortization of deferred revenue from collaborations.
• Expense Increase: Total expenses rose 33.5% to $24.8 million. Research and Development (R&D) expenses increased 35% to $21.9 million due to higher clinical trial costs, manufacturing costs for lead candidates, and increased personnel. General and Administrative (G&A) expenses increased 21% to $2.9 million.
• Widening Loss: Net loss increased by $4.3 million (48.4%) to $13.1 million, reflecting the acceleration of R&D spending outpacing revenue growth.
• Liquidity Position: Cash and cash equivalents decreased by $3.3 million during the quarter due to operating cash burn, though total liquid assets (including marketable securities) remain robust at $81.2 million.

Guidance, Outlook, and Material Events

• Roche Collaboration Termination: In May 2008, Roche exercised its "no cause" termination right for the BCX-4208 license agreement. BioCryst will regain worldwide rights to BCX-4208. Upon termination (180 days from notice), the company expects to recognize $27.3 million in deferred revenue and $8.4 million in deferred expense.
• HHS Contract Status: The $102.6 million, four-year contract with HHS for peramivir development remains unchanged. However, development costs are projected to exceed the contract value. HHS has agreed to fund specific elements of a revised program. The company recorded $4.6 million in revenue related to termination costs of a Phase III i.m. program, with no reserve recorded as costs are deemed recoverable.
• Clinical Updates:
  • Peramivir: The Phase III i.m. program was voluntarily discontinued after enrolling 82 of 600 planned patients to evaluate higher doses in a future Phase II study. The Phase II i.v. study for hospitalized patients is ongoing.
  • Forodesine HCl: A pivotal Phase II trial in cutaneous T-cell lymphoma (CTCL) is ongoing. A second trial for chronic lymphocytic leukemia (CLL) was initiated in Q1 2008.
• Dispute with Mundipharma: A dispute exists regarding manufacturing and development costs for forodesine HCl. The maximum potential exposure is estimated at $2.5 million; no accrual has been made as the company believes it is not responsible for the amounts.
• Cash Burn Projection: Management projects a net cash burn of approximately $25 million to $30 million for the full year 2008. Current resources are deemed sufficient to fund operations for at least the next twelve months.

Investor Verification Checklist

• HHS Reimbursement Risk: Verify the status of discussions regarding the $4.6 million in termination costs and the extent to which HHS will fund the revised peramivir development plan beyond the original $102.6 million cap.
• Roche Termination Impact: Confirm the timeline for the effective date of the Roche termination and the accounting treatment for the $27.3 million revenue recognition.
• Mundipharma Dispute Resolution: Monitor the outcome of the dispute regarding the $2.5 million potential exposure related to forodesine HCl costs.
• Cash Runway: Assess the sufficiency of the $81.2 million in liquid assets against the projected $25-$30 million annual burn rate, considering potential delays in HHS payments or additional capital needs.
• Clinical Trial Outcomes: Track the results of the ongoing Phase II trials for peramivir (i.v.) and forodesine HCl (CTCL and CLL), as these are critical for future revenue generation.